Amgen declares a $2.52 per share dividend for Q4 2026
The payment occurs on December 11, 2026, to stockholders of record by November 20, 2026.
See the latest news and media coverage for Amgen. We track all announcements, press releases, and industry mentions in real time, all in one place.
Multinational biopharmaceutical company
amgen.comLast updated
In short: Amgen raised 2026 guidance after 10% Q2 revenue growth and reported IMDELLTRA survival gains.
The payment occurs on December 11, 2026, to stockholders of record by November 20, 2026.
IMDELLTRA plus IMFINZI reduced death risk by 58% in extensive-stage small cell lung cancer. Results published in the New England Journal of Medicine.
The FDA approved shorter 6-8 hour monitoring windows for initial doses, aiming to facilitate broader community access for extensive-stage small cell lung cancer patients.
The phase 3 DeLLphi-305 trial met primary and secondary endpoints for overall survival, progression-free survival, and objective response rate compared to standard care.
Amgen showcases “excellent” data for its small-cell lung cancer treatment following leaked results f...
Amgen's Imdelltra used in combination with AstraZeneca's immunotherapy Imfinzi reduced the risk of ...
Amgen recently reported quarterly revenue and earnings per share that were above consensus expectations and joined a $30 million Series A round for Arboretum LifeSciences...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Track Amgen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Amgen and other trending companies.